Physician profile
Eva Poon
NPI 1124439617
$2,963.09
in general payments reported to CMS, 2019-2025
45 companies · $1,109 in 2025
The $1,109 reported for 2025 was more than what 86% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $58.02 · 2020: $28.70 · 2021: $275 · 2022: $403 · 2023: $662 · 2024: $428 · 2025: $1,109.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,199.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,198.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $286.35 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $252.12 | 2021-2023 | |
| Abbott Laboratories | $231.33 | 2024 | Freestyle Libre 3 |
| Teleflex LLC | $220.08 | 2023 | Urolift |
| Nalu Medical, INC. | $126.18 | 2022 | |
| Integra Lifesciences Corporation | $119.81 | 2021 | |
| Intercept Pharmaceuticals, INC. | $115.47 | 2023 | Ocaliva |
| Corcept Therapeutics | $106.39 | 2025 | Korlym |
| Tandem Diabetes Care, INC. | $93.62 | 2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Insulet Corporation | $87.29 | 2025 | Omnipod |
| Lilly USA, LLC | $86.98 | 2021-2023 | Mounjaro |
| Genzyme Corporation | $77.45 | 2022-2023 | |
| Boston Scientific Corporation | $75.80 | 2021-2022 | |
| Glaxosmithkline, LLC. | $70.75 | 2022-2024 | Arexvy, Trelegy Ellipta, Shingrix |
| Axsome Therapeutics, INC. | $67.71 | 2025 | Sunosi |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eva Poon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.